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The novel antiviral agent cyclotriazadisulfonamide (CADA) inhibited human immunodeficiency virus (HIV) (IC50, 0.3–3.2 M)
and human herpesvirus 7 (HHV-7) infection (IC50, 0.3–1.5 M) in T-cell lines and PBMCs. When T-cells were pretreated with
CADA for 24 h, they became markedly protected from viral infection. Flow cytometric analysis revealed a significant decrease
in the expression of the CD4 glycoprotein, the primary receptor needed for entry of both viruses. Moreover, the antiviral
activity of CADA correlated with its ability to down-modulate the CD4 receptor. CADA did not alter the expression of any other
cellular receptor (or HIV coreceptor) examined. Time course experiments showed that CD4 down-modulation by CADA
differs in mechanism from the effects of aurintricarboxylic acid, which binds directly to CD4, and phorbol myristate acetate,
which activates protein kinase C. Further analysis of CD4 mRNA levels suggested that CADA was not involved in the
regulation of CD4 expression at a transcriptional level, but very likely at (post) translational levels. This unique mechanism
of action makes CADA an important lead in developing new drugs for treatment of AIDS, autoimmune diseases, and; antiviINTRODUCTION
CD4 is a 55-kDa glycoprotein that is expressed on the
membrane of helper T-cells, monocytes, as well as some
nonlymphocytic leukemia cell lines (Maddon et al., 1985,
1986; Neudorf et al., 1989). It comprises four extracellular
immunoglobulin-like domains, a single spanning trans-
membrane region, and a short cytoplasmic tail. CD4 has
been identified as the main receptor for human immuno-
deficiency virus (HIV) (Dalgleish et al., 1984; Klatzmann et
al., 1984) and human herpesvirus 7 (HHV-7) (Furukawa et
al., 1994; Lusso et al., 1994). During HIV infection, three
HIV-1 proteins, Nef, Env, and Vpu, contribute to the down-
regulation of CD4 (Piguet et al., 1999). Also HHV-7 can
down-regulate the CD4 expression in SupT1 cells and
CD4 T-lymphocytes (Furukawa et al., 1994; Secchiero et
al., 1997). Aurintricarboxylic acid (ATA), which has been
shown to bind directly to CD4, also has activity against
HIV-1 and HHV-7 (Schols et al., 1989a; Zhang et al., 1999).
In addition, phorbol myristate acetate (PMA), which can
rapidly down-modulate CD4 expression in T-lympho-
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342cytes, at both the transcription and translation levels by
activating protein kinase C (PKC), can inhibit HIV-1 and
HHV-7 infection in vitro (Acres et al., 1986; Chowdhury et
al., 1990; Golding et al., 1994; Hoxie et al., 1986; Neudorf
et al., 1991; Touraine et al., 1992; Yasukawa et al., 1995).
It is of particular interest to develop agents that block
binding of the HIV virion to the host cell or entry of the
virus by membrane fusion, because such drugs may be
used to prevent viral infection upon exposure to the virus.
The bicyclam AMD3100 and TAK-779 are compounds
that were found to block HIV entry by binding to the HIV
coreceptors CXCR4 and CCR5, respectively (Baba et al.,
1999; Schols et al., 1997). Several peptides have been
designed to inhibit conformational changes in gp41
(Chan et al., 1998; Jiang et al., 1993; Wild et al., 1994).
Viral resistance may still become a problem with these
approaches and it may be difficult to develop drugs for
these targets that can be taken orally.
Cyclotriazadisulfonamide (CADA) is a synthetic mac-
rocycle (Fig. 1) (Choi, 1989; Samala, 1999; Sodoma, 1996)
that was submitted to the U.S. National Cancer Institute
(NCI) anti-HIV screening program. Based on its broad
range of activity against several strains of HIV in various
cell lines and its novel molecular structure, CADA wasinflammatory disorders. © 2002 Elsevier Science (USA)
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selected by NCI for initial, preclinical anti-HIV drug de-
velopment studies. It was found to be soluble in human,
rat, and mouse plasma at 1.9–3.1 M, to be stable in
plasma (200 h), and to be detectable in the blood-
stream up to 2 h after intravenous injection in mice.
Here, we report that CADA specifically down-modu-
lates cell surface and intracellular CD4 expression. For a
period of up to 4 days, CADA completely blocked CD4
expression in the MT-4 T-cell line, the SupT1 T-cell line,
and peripheral blood mononuclear cells (PBMCs). This
CD4 down-regulating effect resulted in a marked inhibi-
tion of HIV and HHV-7 infection.
RESULTS
Anti-HIV and anti-HHV-7 activity of CADA
In order to confirm the antiviral data of CADA obtained
from the NCI anti-HIV screening program, we evaluated
CADA in our antiviral assays. First, the anti-HIV-1 activity
of CADA was tested. Cells were given fivefold dilutions of
the compound and infected with an optimized dose of
the virus. HIV replication was monitored and when
strong CPE was observed in untreated infected cells, all
samples were then scored for CPE and supernatant was
collected for HIV-1 core antigen (p24 Ag) ELISA. As
summarized in Table 1, CADA inhibits HIV-1 replication
(strains IIIB, RF, and NL4.3) at an IC50 ranging from 0.3 to
3.2 M when evaluated in different CD4 T-cell lines
(such as MT-4 and SupT1) and in PBMCs. Furthermore,
for two HIV-2 strains (ROD and EHO), an IC50 of 0.2 M
was obtained in MT-4 cells.
Comparable data were obtained when CADA was
evaluated for its anti-HHV-7 activity. The IC50s of CADA
for HHV-7 were 0.3 and 1.5 M when evaluated in SupT1
cells and PBMCs, respectively. For CD8 cell-depleted
PBMCs an IC50 of 1.0 M was measured. The CC50
values of CADA in MT-4 cells, SupT1 cells, and PBMC
were 39, 142, and 73 M, respectively. Thus, CADA
equally inhibited HIV and HHV-7 infection.
Specific down-modulation of cell surface CD4 by
CADA
Since the cellular CD4 receptor is the primary receptor
needed for entry of HIV and HHV-7, the effect of CADA on
CD4 expression was evaluated. A selective down-mod-
ulation of CD4 receptor expression in MT-4 T-cells was
observed (Fig. 2A). MT-4 cells were treated with 3.2 M
CADA for 20 h and CD4 expression was then measured
by flow cytometry using a FITC-labeled anti-CD4 mono-
clonal antibody (mAb). As depicted in Fig. 2A, the expres-
sion of the cellular CD4 receptor on CADA-treated cells
was significantly down-modulated compared with the
untreated cells [mean fluorescence intensities (MFI)
were 10.6 and 28.8, respectively]. To measure the back-
ground staining, an isotype control was included (MFI,
3.5). In addition, quantification of the CD4 receptor on
MT-4 cells was performed. Untreated MT-4 cells showed
an antibody binding capacity (ABC) (i.e., the number of
primary mouse antihuman CD4 monoclonal antibodies
per cell) of 43,434, whereas the ABC of CADA-treated
cells dramatically dropped to 5158. Thus, treatment of
MT-4 cells with CADA (3.2 M) results in an 88% reduc-
tion in CD4 expression.
Next, the effect of CADA was evaluated in different cell
types. Figure 2B shows the CD4 receptor down-modula-
tion in the MT-4 T-cell line, the SupT1 T-cell line, and
PBMCs after incubation with CADA for 1 to 4 days. When
MT-4 cells were incubated with CADA (3.2 M) and
stained with anti-CD4 mAb (Leu3a-FITC), a 6-fold de-
crease in surface CD4 antigen expression was observed
after treatment for 1 day. After 4 days of incubation, the
MFI was reduced 9-fold, meaning a significant down-
modulation of the CD4 receptor expression. For the
SupT1 cells (Fig. 2B), a 24-h treatment with CADA (3.2
M) resulted in a 3-fold decrease in the surface CD4
expression. A longer incubation with CADA, i.e., 4 days,
markedly down-modulated the cellular CD4 expression
(an 11-fold reduction in MFI). When CADA was tested in
other cell lines (lymphocytic MOLT-4 and monocytic
THP-1), a down-modulation in CD4 expression was also
observed (6- and 7-fold, respectively). In PBMCs, a 7-fold
decrease in the CD4 expression was measured after
TABLE 1
Antiviral Activity of CADA Against Different HIV Strainsa
HIV strains
IC50 (M)
MT-4 SupT1 PBMC
HIV-1 IIIB 0.3 1.5 0.6
HIV-1 RF 1.5 1.8 1.9
HIV-1 NL4.3 0.5 3.2 1.6
HIV-2 ROD 0.2 NDb ND
HIV-2 EHO 0.2 ND ND
a Cells were given fivefold dilutions of the compound and infected
with an optimized dose of the virus. HIV replication was monitored and
when strong CPE was observed in the positive control (i.e., after 3–5
days for MT4, and 5–7 days for SupT1, 7 days for PBMC), all samples
were scored for CPE and supernatant was collected for determination
of HIV-1 core antigen (p24 Ag) by ELISA.
b ND, not determined.
FIG. 1. Chemical structure of CADA (9-benzyl-3-methylene-1,5-di-p-
toluenesulfonyl-1,5,9-triazacyclododecane).
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incubation with CADA (16 M) for 4 days (Fig. 2B). Fur-
ther flow cytometric analysis of PBMCs revealed a CD4
down-regulating effect of CADA not only in lymphocytes
but also in monocytes (7- and 8-fold reductions of MFI,
respectively). Thus, CADA significantly down-modulated
CD4 expression when evaluated in different human
CD4 cell lines and in PBMCs. Comparable results were
obtained with two other anti-CD4 mAbs, OKT4a and
OKT4; the latter also binds to a different region of CD4
(data not shown).
CADA down-regulates intracellular CD4
The effect of CADA on the intracellular presence of the
CD4 receptor was also investigated. In these experi-
ments, MT-4 cells were cultured in medium alone, in
medium with CADA (3.2 M), or in medium with PMA (8
nM). After 20 h of incubation, cells were washed and
CD4 receptors were stained either intracellularly or ex-
tracellularly (Fig. 3). For the measurement of intracellular
CD4, cells were first incubated with unlabeled anti-CD4
mAb (Leu3a) in order to block the CD4 molecules on the
extracellular surface. After fixation and permeabilization
of the cells, FITC-labeled anti-CD4 mAb (Leu3a-FITC)
was administered and CD4 expression was analyzed
flow cytometrically. For comparison, extracellular CD4
was also assessed. Briefly, cells were directly stained
with Leu3a-FITC, fixed, permeabilized (without adminis-
tration of an intracellular mAb), and analyzed. As shown
in Fig. 3, CADA clearly affected the intracellular detection
of the CD4 molecule (a sevenfold reduction in the MFI).
In fact, the down-modulating effect of CADA on cell
surface and intracellular CD4 expression was very sim-
ilar. In contrast, the effect of PMA, a phorbol ester with
CD4 down-modulating capability, on the expression of
intracellular CD4 was almost nil (the MFI was 81.5% of
that of the untreated cells), whereas PMA clearly down-
regulated cell surface CD4 receptor expression.
No effect of CADA on other cell surface antigens
In addition, the expression of various other surface
antigens was examined in MT-4 cells, SupT1 cells, and
PBMCs after incubation with CADA (16 M) for up to 4
days. As shown in Table 2, among all the surface anti-
gens examined, only CD4 was markedly reduced after
treatment of the cells with CADA for 4 days. In contrast,
the surface antigen expression of the markers CD2, CD3,
CD5, CD8, CD11b, CD25, CD26, CD28, CD38, CD45,
FIG. 3. Cell surface and intracellular CD4 expression in MT-4 cells
after incubation with CADA or PMA. MT-4 cells were cultured for 20 h
in medium alone, in medium with 8 nM PMA, or in medium with 3.2 M
CADA. Gray histograms (extracellular CD4 expression): cells were
washed, stained with anti-CD4 mAb (Leu3a-FITC), and fixed. Black
histograms (intracellular CD4 expression): cells were washed, incu-
bated with anti-CD4 mAb (unlabeled Leu3a) in order to block surface
antigen, fixed, permeabilized, and stained with anti-CD4 mAb (Leu3a-
FITC). Each bar represents the MFI of the CADA- or PMA-treated cells
as a percentage of the MFI of the untreated cells. Similar results were
obtained in a repeat experiment and also in SupT1 cells.
FIG. 2. (A) CD4 down-modulation in MT-4 cells after incubation with
3.2 M CADA for 20 h. The figure shows the cell surface CD4 expres-
sion of untreated and CADA-treated cells after staining with Leu3a-
FITC. Similar results were obtained in several repeat experiments. (B)
Cell surface CD4 down-modulation in MT-4 and SupT1 cells and
PBMCs after incubation with CADA for 1 to 4 days. On day 0, CADA (3.2
M for MT-4 and SupT1; 16 M for PBMC) and control medium were
administered to the cell cultures. At the indicated time points, cells
were stained with Leu3a-FITC (MT-4 and SupT1) or Leu3a-PE mAb
(PBMCs). The figure shows the cell surface CD4 expression of CADA-
treated cells after 1, 2, 3, and 4 days of incubation. Each bar represents
the MFI of the CADA-treated cells as a percentage of the MFI of the
untreated cells. One representative experiment of two is shown.
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CD45RA, CD57, CD71, HLA-DR, and TCR- remained
unaffected after treatment with CADA (Table 2). As de-
picted in Fig. 4, cell surface expression of the HIV core-
ceptor/chemokine receptor CXCR4 also remained un-
changed after incubation of MT-4 cells with 3.2 M
CADA for 20 h (MFI were 38.4 and 37.0 for CADA-treated
and control cells, respectively), whereas CD4 expression
was clearly down-regulated in these cells. In contrast,
when MT-4 cells were cultured in the presence of 8 nM
phorbol ester PMA for 20 h, a significantly down-modu-
lating effect of PMA on CD4 and on CXCR4 expression
was observed (ninefold and fourfold decreases, respec-
tively) (Fig. 4). Similar results were obtained in the SupT1
T-cell line (data not shown). Even a short exposure (i.e.,
2 h) of MT-4 or SupT1 cells to PMA (160 nM) remarkably
down-regulated the surface expression of CD4 as well
as CXCR4, an observation which was described by
Signoret et al. (1997). However, CADA only affected CD4
and not CXCR4 expression after 20 h of incubation.
Additionally, in PBMCs CADA had no down-modulating
effect on the cellular expression of either of the major
HIV coreceptors CXCR4 and CCR5 (MFI of CXCR4 stain-
ing, 76 and 99 for control and CADA-treated cells, re-
spectively). Furthermore, CADA (at 16 M) did not inter-
act with the stromal cell-derived factor 1 (SDF-1) or
regulate on activation normal T-cell-expressed and se-
creted (RANTES)-induced intracellular Ca2 signaling in
CXCR4- or CCR5-transfected cells (data not shown).
CADA does not affect CD4 mRNA levels
Further attempts were made to elucidate the mecha-
nism of CADA’s action on CD4 expression. First, steady-
state levels of total CD4 were compared in untreated and
CADA-treated cells by Western blot analysis. In accor-
dance with the results from flow cytometry (i.e., cell
surface and intracellular CD4 measurement), the total
CD4 protein levels were significantly lower in SupT1 and
MT-4 cells treated with 0.64 M CADA (Fig. 5, lanes 3
and 7), compared with untreated cells (lanes 1 and 5). A
higher dose of the compound (3.2 M) resulted in an
almost complete loss of CD4 (lanes 4 and 8). Even a
TABLE 2
Cell Surface Antigen Expression in MT-4, and SupT1 Cells and PBMCs Cultured for 4 Days in the Absence or the Presence of CADA (16 M)
Surface molecule
MT-4 SupT1 PBMC
Control CADA Control CADA Control CADA
CD2 1.5a 2.6 2.4 0.5 96.2 90.7
CD3 2.3 5.9 1.4 2.7 89.7 89.4
CD4 95.6 6.3 96.4 1.2 60.3 0.2
CD5 99.6 99.1 96.1 93.9 82.0 80.6
CD8 2.8 3.5 98 92.3 25.3 25.1
CD11b 7.0 9.7 0.5 0.6 19.9 12.3
CD25 96.7 93.3 2.3 1 37.6 35.5
CD26 1.4 3.2 0.2 0.3 1.4 3.2
CD28 6.6 6.6 98.7 90.8 92.0 89.6
CD38 95 84.5 99.5 99.1 78.9 73.2
CD45 2.7 3.6 99.5 99.6 98.9 98.3
CD45RA 2.7 2.0 2.4 0.5 69 64.3
CD57 0.7 1.5 73 82.4 4.9 2.3
CD71 85.2 98.8 39.8 33.9 29.3 27.6
HLA-DR 98.7 98.7 1.9 1.7 28 27
TCR/ 0.8 1.1 2.5 1.6 80.4 82.3
a Percentage of cells positive for cell surface antigen staining.
FIG. 4. Effect of CADA and PMA on the cell surface expression of
CXCR4 and CD4. MT-4 cells were cultured for 20 h in medium alone
(open histogram), in medium with 3.2 M CADA (gray histogram), or in
medium with 8 nM PMA (black histogram). Cells were washed and
stained with anti-CD4 mAb (Leu3a-FITC) or anti-CXCR4 mAb (12G5-PE).
Each bar represents the MFI as a percentage of the MFI of the
untreated cells. The results shown are from one representative exper-
iment. Comparable results were obtained in SupT1 cells.
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treatment with 0.13 M CADA slightly reduced the CD4
level in these cells (Fig. 5, lanes 2 and 6).
A possible mechanism of CD4 down-regulation by
CADA could be the interaction of the compound on the
transcriptional level. Therefore, CD4 mRNA levels in
SupT1 cells relative to control mRNA were examined in
the presence and the absence of CADA (3.2 M). Total
RNA was isolated from untreated and treated cells, re-
verse transcribed, and subjected to a CD4-specific PCR.
cDNA preparations were serially diluted (3-fold) and am-
plified by PCR for CD4 and -actin. As depicted in Fig. 6,
similar mRNA levels for CD4 were obtained in CADA-
treated cells and untreated cells, meaning that CADA did
not affect the transcription of CD4 although the cell
surface CD4 expression was significantly decreased as
measured by flow cytometry (a 9-fold reduction in MFI).
In addition, when the effect of CADA was tested on the
U87.CD4 cell line, a transformed human glioma cell line
constitutively expressing CD4 via a nonendogenous en-
hancer/promoter, a marked down-modulation of surface
CD4 expression was observed (a 10-fold reduction in
MFI), indicating that CADA does not act on the endoge-
nous CD4 enhancer/promoter.
Kinetics of CD4 down-modulation by CADA
Next, the kinetics of the CD4 down-regulating activity
of CADA was compared to those of several other com-
pounds. The anionic polymer ATA can directly inhibit the
binding of the OKT4a/Leu3a mAb to the CD4 receptor
(Schols et al., 1989a). When SupT1 cells were treated
with ATA (118 M) for 20 min, a 9-fold decrease in cell
surface CD4 staining was observed. Similar results were
obtained in PBMCs, where again ATA directly blocked
the binding of Leu3a mAb to the CD4 receptor within 20
min of incubation (a 15-fold decrease). In contrast, when
SupT1 cells were incubated with PMA (8 nM) for 30 min,
only a slight CD4 decrease in these cells could be
detected (the MFI was 87.3% of that of untreated cells).
However, CD4 expression was dramatically decreased
after incubation with PMA for 4 h (a 6-fold reduction in
MFI) (Fig. 7). Compared to PMA, CADA had a different
time-dependent effect on the down-modulation of CD4.
The CD4 expression in SupT1 cells treated with CADA
(3.2 M) for 1 h was still as high as that in untreated cells
(Fig. 7), whereas PMA treatment resulted in a CD4 down-
modulation of more than 50%. Remarkably, in CADA-
treated SupT1 cells a more than 50% decrease in CD4
expression became only clearly visible after an incuba-
tion of 12 h (Fig. 7). The CD4 expression dropped be-
neath 10% of the control after a 4-day treatment with
CADA (see Fig. 2). Thus, the kinetics of the CD4 receptor
down-regulation elicited by CADA treatment differed
from that of PMA and ATA treatment. Also, the PKC
blocker staurosporine, which can block the PMA effect
on down-modulation of CD4, did not show any effect on
the down-regulation of CD4 with CADA (data not shown).
The antiviral potency of CADA correlates with its
ability to down-modulate CD4
The question arises whether the antiviral potency of
CADA was primarily due to its ability to down-regulate
the CD4 receptor. A dose–response effect of CADA on
FIG. 5. Decreased protein level of CD4 in SupT1 and MT-4 cells after
treatment with CADA. Cells were treated with different concentrations
of CADA for 3 days and subjected to Western blotting analysis as
described under Materials and Methods.
FIG. 6. RT–PCR analysis of CD4 mRNA levels in untreated (lanes 1–5)
or CADA-treated (lanes 6–10) SupT1 cells. Cells were given medium or
3.2 M CADA for 4 days and then subjected to total RNA isolation.
cDNA preparations were serially diluted (threefold) and amplified by
PCR for CD4 and -actin. Lanes 1 and 6, dilution 1/1; lanes 2 and 7, 1/3;
lanes 3 and 8, 1/9; lanes 4 and 9, 1/27; and lanes 5 and 10, 1/81.
Comparable results were obtained in MT-4 cells.
FIG. 7. Kinetics of CADA- and PMA-induced CD4 modulation in
SupT1 cells. The MFI of the Leu3a-FITC (anti-CD4 mAb) staining are
depicted as a percentage of the MFI of untreated cells. Cells were
exposed to CADA (3.2 M) or PMA (8 nM), and at the indicated time
points after administration of the compounds the CD4 receptor expres-
sion was assessed by flow cytometry. One representative experiment
of three is shown.
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HIV infection and on CD4 down-modulation is combined
in Fig. 8. MT-4 cells were infected with the HIV-1 strain
NL4.3 in the presence of different doses of CADA (16, 3.2,
0.64, and 0.13 M). After 4 days of incubation, when CPE
was clearly visible, supernatant was collected and viral
replication was measured by p24 Ag ELISA. As shown in
Fig. 8, CADA at concentrations of 16 and 3.2 M com-
pletely blocked viral replication, whereas at 0.64 M 25%
inhibition of virus production was detected. A lower dose
of the compound (i.e., 0.13 M) had no inhibitory effect on
HIV-1 replication. Thus, the IC50 of CADA in this experi-
ment was 1.1 M. When the CD4 receptor expression
was measured on CADA-treated MT-4 cells, a similar
dose-dependent effect of CADA on the MFI was ob-
served. High concentrations of CADA (i.e., 16 and 3.2
M) resulted in a significant down-modulation in CD4
receptor expression, as evident from the low MFI values.
At 0.64 M the MFI was 54% of that of untreated cells,
resulting in an IC50 of 0.76 M. These results demon-
strate that the CD4 down-regulating activity of CADA
directly correlates with its anti-HIV potency.
CADA inhibits HIV-1 entry
In addition, an HIV-1 entry PCR was set up in order to
further prove that CADA can efficiently block HIV infec-
tion at a very early step. A semiquantitative HIV-1 LTR
R/U5-specific PCR was performed on total DNA isolated
from SupT1 or MT-4 cells at 2 h after infection with the
HIV-1 strain NL4.3. Synthesis of the LTR R/U5 DNA tran-
script, also known as “strong-stop DNA,” is the first step
in the reverse transcription process and is accomplished
at a very early stage of the infection, immediately after
viral entry and uncoating. Thus, MT-4 and SupT1 cells
were treated with CADA (3.2 M) for 2 and 4 days,
respectively, resulting in significantly reduced CD4 ex-
pression (an eightfold reduced MFI compared to the
nontreated cells). As shown in Fig. 9, CADA-pretreated
cells were markedly less susceptible to viral entry, dem-
onstrating that CADA acts as a viral entry inhibitor by
reducing the expression of the main HIV receptor. As a
control for the viral entry assay, treatment of the cells
with AMD3100 (12 M), a strong and specific antagonist
of the HIV coreceptor CXCR4, also blocked HIV-1 entry
(Fig. 9).
Enhanced anti-HIV activity of CADA after
pretreatment of the cells
As could be expected from the time course of the CD4
down-modulating effect of CADA, preincubation of MT-4
cells with CADA for 24 h markedly enhanced its antiviral
activity. Table 3 presents the results for MT-4 cells pre-
treated with CADA (8 M) for 1 day and then infected
with the HIV-1 strain NL4.3 or RF in the absence or the
presence of CADA. HIV-1 infection in CADA-pretreated
MT-4 cells was substantially decreased, compared to
that in the untreated MT-4 cells (a 4.5-fold reduction in
p24 core antigen levels). Also, when the cells were pre-
treated with CADA, administration of CADA at 0.64 M
then completely blocked viral replication. Comparable
results were obtained with SupT1 cells and PBMCs (data
not shown).
For HHV-7 infection, pretreatment of SupT1 cells with
CADA (8 M) for 1 day resulted in a decrease in HHV-7
infection of more than threefold compared to that in
FIG. 9. PCR-based detection of virus entry into MT-4 and SupT1 cells.
Cells were treated with 3.2 M CADA for 2 (MT-4) or 4 (SupT1) days,
resulting in significantly reduced CD4 expression. For comparison,
cells were also treated with 12 M AMD3100 for 30 min. Then cells
were infected with HIV-1 NL4.3, and 2 h after infection total DNA was
extracted from the cells and analyzed by a semiquantitative PCR using
HIV-1-specific primers from the LTR R/U5 region. DNA samples from
mock-infected cells produced no signal (lanes 1 and 5). DNA recovery
was controlled by PCR with -actin-specific primers.
FIG. 8. Correlation between anti-HIV potency and CD4 down-modu-
lating capability of CADA. MT-4 cells were infected with NL4.3 in the
presence of different doses of CADA. After 4 days, supernatant was
collected and analyzed for its p24 content (vertical bars). In parallel,
uninfected MT-4 cells were treated with the same doses of CADA, and
CD4 expression was analyzed flow cytometrically after 4 days of incu-
bation. The MFI of the Leu3a-FITC staining is depicted for the different
doses of CADA (line). One representative experiment of two is shown.
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untreated SupT1 cells. Thus, as expected from the data
presented in Fig. 2, pretreatment of the cells with CADA
for 24 h clearly enhanced its antiviral potency.
DISCUSSION
Incubation of CD4 T cells with CADA resulted in a
down-modulation of the cell surface CD4 expression. In
addition, intracellular CD4 expression was also strongly
blocked after incubation with CADA. Further Western
blotting analysis of the total CD4 protein levels confirmed
the CD4 down-regulating activity of the compound. Ex-
cept for the CD4 receptor, CADA did not have effect on
any of the other cellular receptors evaluated so far. As in
SupT1 cells, a significant down-modulating effect on
CD4 expression was also detected in PBMCs. Thus, in
all cell lines tested, CADA acted as a very specific
down-modulator of CD4. Interestingly, even in the
U87.CD4 cell line, a transformed human glioma cell line
constitutively expressing CD4 via a nonendogenous en-
hancer/promoter (Clapham et al., 1991), a marked down-
modulated of surface CD4 expression was observed.
This suggested that interaction of CADA on CD4 mRNA
regulation seemed very unlikely. Indeed, when the effect
of CADA was evaluated on the transcriptional level of
CD4, no differences in CD4 mRNA production were mea-
sured in CADA-treated T-cells compared to untreated
cells (Fig. 6). The data with the kinetics of CADA indicate
that the timing of the CD4 down-regulating effect of
CADA varied somewhat from one cell line to another (in
MT-4 cells the CD4 down-modulation began to occur
after 12 h, whereas in SupT1 cells and PBMCs the effect
of CADA was more pronounced after 4 days of incuba-
tion). This relatively long incubation time before modula-
tion of CD4 becomes clearly visible suggests that CADA
may affect CD4 expression at the translation level.
As three CD4 binding events are needed to efficiently
activate HIV-1 Env trimers (Layne et al., 1990), multimeric
CD4 binding is required for HIV infection, further implying
that receptor density plays a crucial role in the efficiency
of viral infectivity (Platt et al., 1997). Davis et al. reported
that CD4 T-cells bind approximately 49,000 CD4 (Leu3a)
antibody molecules and that this binding is bivalent,
suggesting 98,000 CD4 antigen molecules on the sur-
face of these cells (Davis et al., 1998). Our data concern-
ing the quantification of the CD4 receptor showed a
similar result (approximately 43,000 CD4 antibody (Ab)
molecules/cell). Interestingly, after treatment with CADA
the amount of CD4 Ab bound to the cells dropped to
approximately 5000/cell. Thus, CADA is able to reduce
the CD4 receptor density by almost 90%. It has been
reported that CD4 receptor density will significantly im-
pact the efficiency of viral entry and when the CD4 level
becomes limiting (less than 10,000 CD4 molecules/cell) it
strongly inhibits viral infection (Kabat et al., 1994; Platt et
al., 1997); primary HIV isolates especially seem to be
much more dependent on the level of CD4 expression
(Kabat et al., 1994; Platt et al., 2000). When evaluated
against six different primary HIV-1 isolates in PBMCs,
CADA showed a potent (but variable) activity ranging
from 0.002 to 2.3 M. Although CD4-independent viruses
have been described (Hoffman et al., 1999), these are
much more sensitive to neutralization by antibodies,
which could explain the rarity of CD4-independent wild-
type HIV variants (Edwards et al., 2001; Kolchinsky et al.,
2001). A CD4-lowering drug, such as CADA, not only
inhibits viral infection by blocking viral entry (Fig. 9), but
also can make the virus more prone to elimination by the
neutralizing action of antibodies. Furthermore, as several
domains of CD4 play an important role in regulating HIV
entry of cells (Poulin et al., 1991), a specific down-mod-
ulator of the complete CD4 molecule may be considered
an effective antiviral agent.
The anionic polymer ATA inhibits HIV-1 replication by a
direct interaction with the CD4 receptor (Schols et al.,
1989a). It can also inhibit HHV-7 infection, probably due
to its interference with the CD4 receptor (Zhang et al.,
1999). Inhibition of CD4 expression by ATA can be de-
tected immediately after incubating the cells with ATA. In
contrast, our data show that incubation of the cells with
CADA for 1 h did not affect CD4 receptor expression,
suggesting that the down-modulation of CD4 expression
by CADA is not due to direct binding to the surface CD4
receptor. Previous studies have shown that the phorbol
ester PMA can down-regulate CD4 expression at the
transcriptional and translational levels (Neudorf et al.,
1991). Phorbol esters can also down-modulate the CD4
receptor by activating PKC (Chowdhury et al., 1990). In
addition, it has been shown that PMA can inhibit HHV-7
infection (Yasukawa et al., 1995) and HIV-1 infection
(Touraine et al., 1992). Furthermore, phorbol esters inhibit
HIV-induced syncytia formation through down-modula-
tion of the surface CD4 receptor (Chowdhury et al., 1990)
or by modulating an accessory component in the CD4
cells (Golding et al., 1994). From our data we can con-
clude that the down-modulation of CD4 by CADA has a
TABLE 3
Levels of p24 Antigen (pg/ml) in the Supernatant of MT-4 Cells
Infected with HIV-1 Strains NL4.3 and RF
NL4.3 RF
Pretreateda Untreated Pretreateda Untreated
Medium
CADA 34,839 158,627 42,853 100,002
(3.2 M) 5 5 5 5
(0.64 M) 5 63,098 5 56,139
(0.13 M) 33,785 127,838 35,894 75,118
a Cells were pretreated with CADA (8 M) for 24 h, and the com-
pound was added again after HIV infection at the indicated concentra-
tions.
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different time-dependent course than that of PMA. First,
PMA affects the cell surface CD4 expression in a much
faster way than CADA does. Second, CADA also down-
modulated intracellular CD4 expression, an effect that
was not seen when cells were treated with PMA. PMA
also down-regulated CXCR4 quickly, whereas CADA is
not capable of doing so. Finally, the PKC inhibitor stau-
rosporine does not influence the down-modulation of
CD4 expression by CADA. This suggests that CD4 re-
ceptor down-regulation by CADA does not occur through
activation of PKC.
Gangliosides, which are acidic glycolipids, can also
induce a selective loss of CD4 without affecting other
surface molecules and can block CD4-mediated HIV-1
infection (Chieco-Bianchi et al., 1989; Kawaguchi et al.,
1989; Offner et al., 1987). Yet the effects of gangliosides
on CD4 are neutralized in the presence of serum albumin
(Chieco-Bianchi et al., 1989). Therefore, the effect of
human serum on the anti-HIV activity of CADA was stud-
ied in our antiviral assays, and we found that 10% human
serum did not significantly alter the antiviral potency of
CADA.
Persistently HIV-infected cells express HIV glycopro-
teins on their cell surfaces and thus bind to the CD4
molecule of uninfected CD4 cells. To elicit syncytium
formation, the viral envelope protein must bind to the
CD4 receptor on the surface of the CD4 T cell, and
compounds shown to interact with CD4–gp120 binding
have activity in these cell assays (Schols et al., 1989b).
When administered directly into the syncytia formation
assay, CADA was not able to prevent the formation of
giant cells (data not shown), leading to the conclusion
that CADA does not interfere directly with the CD4–
gp120 interaction. Furthermore, this conclusion got more
support when CADA was tested in our virus binding
assay, where again no inhibitory effect of the compound
could be observed on the virus–cell interaction, whereas
administration of pentosan polysulfate (PPS) resulted in
a marked blocking of viral binding, as expected (Schols
et al., 1989a) (p24 values were 5.1, 5.4, and 1.3 ng/ml for
control and CADA- and PPS-treated cells, respectively).
However, when SupT1 cells were pretreated with CADA
in order to down-regulate the cellular CD4 expression
before being added to (untreated) HIV-infected HUT78
cells, a clearly inhibitory effect of CADA on HIV-induced
giant cell formation was observed, as evident from a
significantly reduced CPE.
That the antiviral activity of CADA can be related to the
specific target CD4 has been further stressed by the
evaluation of CADA against several resistant HIV-1
strains. When CADA was tested in an antiviral assay
using dextran sulfate-resistant NL4.3 virus (Este´ et al.,
1997), AMD3100-resistant NL4.3 virus (De Vreese et al.,
1996), or SDF-1-resistant NL4.3 virus (Schols et al.,
1998), no loss of activity was detected compared to that
in the wild-type NL4.3 virus (data not shown). Thus,
CADA seems to retain its anti-HIV activity even if HIV-1
strains used were resistant to polyanionic or CXCR4-
antagonistic compounds. Also, when NL4.3 wild-type vi-
rus stock was pretreated with CADA prior to infection, a
similar CPE was observed to that with untreated virus,
indicating again that CADA does not directly interact with
the virion. Furthermore, a strong correlation between
CD4 down-modulation and the antiviral activity of several
CADA analogs has been observed, supporting the con-
clusion that the antiviral activity is solely due to their CD4
down-regulating potency (K. Vermeire, manuscript in
preparation). The selection of an HIV-1 strain resistant to
CADA, which has currently been in progress for 4
months without success, lets us suspect that resistance
of HIV to CADA will develop slowly, as could be expected
from the crucial role of the CD4 receptor in viral entry.
In conclusion, CD4 structure-based drug design may
lead to new roads for antiviral research (Li et al., 1998).
Our study has demonstrated that CADA down-modulates
CD4 by a unique and very specific mechanism and,
consequently, inhibits HIV-1 and HHV-7 infection. This
discovery may open the door to a new approach to the
chemotherapy of AIDS, autoimmune diseases, and in-
flammatory disorders, such as rheumatoid arthritis, pso-
riasis, and multiple sclerosis.
MATERIALS AND METHODS
Viruses and cell cultures
The IIIB, RF, and NL4.3 strains of HIV-1 and the EHO
and ROD strains of HIV-2 were obtained from the NIAID
AIDS Reagent Program (Bethesda, MD). The KHR strain
of HHV-7 was kindly provided by Dr. K. Yamanishi (De-
partment of Microbiology, Osaka University School of
Medicine, Osaka, Japan). The CD4 cell lines MT-4,
SupT1, HUT-78, MOLT-4, and THP-1 were obtained from
the American Type Culture Collection (Rockville, MD)
and cultured in RPMI 1640 medium (Gibco BRL, Gaith-
ersburg, MD) with 10% heat-inactivated fetal calf serum
(FCS) (Biowhittaker Europe, Verviers, Belgium) and 2 mM
L-glutamine (Gibco BRL). Human astroglioma U87 cells
expressing human CD4 (U87.CD4) (Clapham et al., 1991)
were kindly provided by Dr. Dan R. Littman (Skirball
Institute of Biomolecular Medicine, New York University
Medical Center, New York, NY) and were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen, Paisley,
UK) containing 10% FCS, 0.01 M HEPES buffer (Invitro-
gen), and 0.2 mg/ml geneticin (G-418 sulfate) (Invitrogen).
The HHV-7 stock was made in the SupT1 cell line,
whereas the HIV-1 stocks were made in MT-4 cells. Buffy
coat preparations from healthy donors were obtained
from the Blood Bank in Leuven. Peripheral blood mono-
nuclear cells (PBMCs) were first isolated by density
gradient centrifugation over Lymphoprep (d  1.077
g/ml) (Nycomed, Oslo, Norway). CD8 magnetic beads
(Dynal AS, Oslo, Norway) were added to remove the
349SPECIFIC DOWN-MODULATION OF CD4
CD8 T lymphocytes. The PBMCs and CD8 T-cell-de-
pleted PBMCs were stimulated with 2 g/ml of phytohe-
magglutinin (PHA) (Sigma Chemical Co., Bornem, Bel-
gium) for 3 days at 37°C.
Compounds and monoclonal antibodies
Aurintricarboxylic acid (ATA; M r 422.3), phorbol myris-
tate acetate (PMA; M r 616.8), and pentosan polysulfate
(PPS; M r 3100) were purchased from Sigma Chemical
Company. The bicyclam AMD3100 was synthesized as
described previously (Bridger et al., 1995). The com-
pound CADA (M r 618, Fig. 1) was synthesized by Dr.
Thomas W. Bell (Department of Chemistry, University of
Nevada, Reno, NV) by a modification of the methods
developed in Stony Brook (Department of Chemistry,
State University of New York, Stony Brook, NY). CADA
was dissolved at 16 mM in DMSO.
The mAbs labeled with phycoerythrin (PE) or FITC
used were the following: CD2, CD3, CD4 (Leu3a,
RPA-T4), CD5, CD8, CD11b, CD25, CD26, CD26, CD28,
CD38, CD45, CD45RA, CD57, CD71, HLA-DR, TCR-,
CXCR4, and CCR5. All mAbs were purchased from BD
Biosciences (Erembodegem, Belgium). The anti-CD4
mAbs OKT4 and OKT4a were purchased from Ortho
Diagnostic Systems (Beerse, Belgium). The HIV-1 p24
antigen ELISA kit was purchased from NEN (Brussels,
Belgium). The specific mAb to HHV-7 (RK-4) (Advanced
Biotechnologies, Columbia, MD) recognizing an early
HHV-7 protein was used to detect HHV-7-infected cells.
Antiviral activity
For HIV-1, PBMCs were incubated with the HIV-1
strains IIIB, RF, and NL4.3 for 2 h at 37°C. Then the cells
were washed with warm medium and seeded into 48-
well flat bottom plates (Iwaki, Japan). Fivefold dilutions of
the compound were added to each well, together with 1
ng/ml of IL-2 (R&D Systems Europe, Abingdon, Oxon,
UK). The anti-HIV-1 assays were also performed with
MT-4 and SupT1 cells. Fivefold dilutions of CADA in 100
l were added to 96-well flat bottom plates (Iwaki). Then
6  104 MT-4 cells or SupT1 cells were added in 50 l of
medium, and finally 50 l of diluted HIV-1 stocks (strains
IIIB, RF, and NL4.3) was added to each well. Cytopathic
effect induced by the virus was checked regularly micro-
scopically. When strong CPE was observed in the posi-
tive control (i.e., untreated HIV-1-infected cells), all sam-
ples were scored for CPE at the same time regardless of
the CPE present, and the supernatant of each sample
was then collected (at the same time), stored at 20°C,
and analyzed for HIV-1 core antigen by p24 Ag ELISA.
For HHV-7, fivefold dilutions of CADA were added in
500 l of culture medium in 24-well flat bottom plates
(Iwaki), whereupon 2  105 SupT1 cells were added in
400 l of culture medium. After 30 min of incubation at
room temperature, 100 l of HHV-7 stock was added to
each well. HHV-7-infected and mock-infected SupT1
cells were cultured in a final volume of 1 ml of medium in
the absence of CADA. On day 4, half of the medium and
the cells were replaced and fresh medium without new
compound was added. This procedure was repeated
every 2 or 3 days. In the anti-HHV-7 assay in PBMCs and
CD8 T-cell-depleted PBMCs, fivefold dilutions of CADA
were added in 250 l of culture medium in 24-well
plates, and then 2  106 cells were added in 400 l of
culture medium. After 30 min of incubation at room tem-
perature, 100 l of HHV-7 stock was added together with
IL-2 (1 ng/ml). At day 4, 1 ml of fresh medium containing
IL-2 (1 ng/ml) was added to each well. The CPE was
checked regularly microscopically. When CPE was ob-
served, the HHV-7 antigen expression was monitored by
flow cytometry, as described previously (Zhang et al.,
1999).
Flow cytometric analyses
To study the effect of CADA on surface CD4 antigen
expression, MT-4 cells, SupT1 cells, HHV-7-infected
SupT1 cells, and PBMCs were incubated with a serial
fivefold dilution of CADA (16, 3.2, 0.64, and 0.13 M) or
medium at 37°C. Cell surface CD4 antigen expression
was analyzed at different time points (up to 4 days). After
washing with phosphate-buffered saline (PBS) contain-
ing 2% fetal calf serum (FCS), cells were incubated with
mAb for 20 min at 4°C. Then the cells were washed, fixed
with 1% formaldehyde, and analyzed by a FACScalibur
(BD, San Jose, CA).
For comparative assessments on CD4 receptor ex-
pression in T cells, experiments with ATA and PMA were
also conducted. Briefly, CADA (16 or 3.2 M), ATA (118
M), and PMA (8 nM) were added to the cells for an
incubation time between 20 min and 4 days, and cell
surface CD4 antigen expression was analyzed as de-
scribed above.
In order to investigate the effect of CADA on intracel-
lular CD4 protein expression, cells were incubated with
CADA (16 or 3.2 M), PMA (8 nM), or medium at 37°C.
The intracellular CD4 antigen expression was evaluated
on day 1. Briefly, the cells were first washed with PBSA
(PBS, 0.1% NaN3, 2% NCS) and then incubated with un-
labeled CD4 mAb (Leu3a) to block the surface CD4
expression. After 30 min of incubation at 4°C, the cells
were washed and resuspended in 1% formaldehyde for
1 h at 4°C. Then the cell pellets were resuspended in
0.2% Tween 20 at 37°C. After 15 min of incubation, the
cells were centrifuged and incubated with CD4 mAb
(Leu3a-FITC) for 30 min at 4°C, washed again, and an-
alyzed by flow cytometry.
Quantitative analysis of CD4 receptor
DAKO QIFIKIT (DAKO, Glostrup, Denmark) was used
for the quantitative determination of cell surface CD4
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receptor by flow cytometry. The antigen quantity is ex-
pressed in ABC units, i.e., the number of primary mouse
monoclonal antibodies per cell or microbead. According
to the manufacturer’s user manual, 4  105 MT-4 cells
were incubated (30 min, 4°C) with a saturating concen-
tration (10 l) of unconjugated primary mouse monoclo-
nal antibody against human CD4 (Leu3a pure, BD). As a
negative control, an irrelevant mouse monoclonal anti-
body of the same isotype (IgG1) was included (negative
control, DAKO). Cells were washed and FITC conjugate
(FITC-conjugated goat antimouse immunoglobulins,
DAKO) was administered to the cells as well as to the
Set-up and Calibration Beads. After an incubation of 45
min (4°C), cells and beads were washed, fixed with 1%
formaldehyde, and analyzed by a FACScalibur (BD). For
the calculation of the ABC of the samples, the MFI of
each bead population of the Calibration Beads (bearing
different but exact known numbers of monoclonal Ab
molecules) was defined and used for the construction of
the calibration curve.
Time-of-addition experiments
To further investigate the antiviral effect of CADA, time-
of-addition assays were performed. Briefly, 5  106
SupT1 or MT-4 cells were pretreated with CADA at 8 M.
After 1 or 4 days of pretreatment with CADA, the cells
were evaluated for CD4 expression level and infected
with HHV-7 or HIV-1, as described above.
Virus binding assay
MT-4 cells (5  105) were incubated with compound
(16 M CADA or 8 M PPS) or medium for 30 min at
37°C. Next, supernatant containing 1  105 pg of p24
antigen of HIV-1 NL4.3 virus was added. One hour after
infection, cells were washed three times with PBS (with
1% FCS) and lysed and p24 antigen bound to the cells
was determined by a commercial p24 Ag ELISA test
(NEN, Brussels, Belgium).
In order to investigate if CADA has a direct inhibitory
effect on the virus, HIV-1 NL4.3 virus stock (650 ng/ml)
was pretreated with 16 M CADA for 2 h at 37°C prior to
infection. Next, the virus stock was diluted to 0.5 ng/ml
for the infection of MT-4 cells, leaving less than 16 nM
residual CADA in the supernatant of the infected cells.
When strong CPE was observed in the positive control
(i.e., untreated HIV-1-infected cells), all samples were
scored for CPE at the same time regardless of the CPE
present, and the supernatant of each sample was then
collected (at the same time), stored at 20°C, and ana-
lyzed for HIV-1 core antigen by p24 Ag ELISA.
Syncytium formation assay
Fivefold dilutions of CADA or anti-CD4 mAb (RPA-T4)
were added in 500 l of culture medium in 24-well flat
bottom plates. Then 1  106 SupT1 cells were added in
250 l of culture medium, followed by 1  106 HIV-1
(IIIB)-infected HUT-78 cells in 250 l of culture medium.
The HIV-1-induced cell fusion was checked microscopi-
cally 24 h after the start of the coculture. In some exper-
iments, only the SupT1 cells were pretreated with CADA
(3.2 M) for 4 days and added to the (untreated) IIIB-
infected HUT-78 cells.
HIV entry PCR
Cells (SupT1 or MT-4) were seeded in 24-well plates at
1  106 cells per well. Virus stocks (diluted to a p24 titer
of 10,000 pg/ml) were treated with 500 U/ml of RNase-
free DNase (Roche Molecular Biochemicals) for 1 h at
room temperature. Then the cells in each well were
infected with 1000 pg of p24. After incubation at 37°C for
2 h, the cells were washed twice with PBS and total DNA
was extracted from the infected cells using the QIAamp
DNA Mini Kit (QIAGEN, Hilden, Germany). The DNA was
eluted from the QIAamp spin columns in a final volume of
200 l of elution buffer. Then 10 l of each DNA sample
was subjected to 38 cycles of HIV-1 LTR R/U5-specific
and 28 cycles of -actin-specific PCR on a Biometra T3
Thermocycler. Each cycle comprised a 45-s denaturation
step at 95°C, a 45-s annealing step at 61°C, and a 45-s
extension step at 72°C. The primers used were LTR R/U5
sense primer 5-GGCTAACTAGGGAACCCACTG-3 (nu-
cleotides 496 to 516, according to the HIV-1 HXB-2 DNA
sequence, see Ratner et al., 1985), LTR R/U5 antisense
primer 5-CTGCTAGAGATTTTCCACACTGAC-3 (nucleo-
tides 612 to 635), -actin sense primer 5-TCTGGCG-
GCACCACCATGTACC-3 (nucleotides 2658 to 2679),
-actin antisense primer 5-CGATGGAGGGGCCGGAC-
TCG-3 (nucleotides 2961 to 2980). The reaction mixtures
contained PCR buffer (supplied with the enzyme), 200
M concentrations of dATP, dGTP, dCTP, and dTTP (Life
Technologies), 0.4 M concentrations of the forward and
reverse primers, and 0.5 U of SuperTaq DNA polymerase
(HT Biotechnology, Cambridge, England) in a total vol-
ume of 25 l. After gel electrophoresis through a 2%
agarose gel, the amplified DNA fragments were visual-
ized by ethidium bromide. In preliminary experiments,
the exponential range of the PCR amplification curve
was determined for both the HIV-1 LTR R/U5 and the
-actin PCRs by varying the amount of input DNA and the
number of PCR cycles. Based on these experiments,
appropriate conditions were chosen to perform the
PCRs.
RT–PCR analysis of CD4 expression
Total RNA was isolated from approximately 5  106
cells using the RNeasy Mini Kit (QIAGEN). To eliminate
any possible contamination by genomic DNA, DNase
treatment (RNase-free DNase Set, QIAGEN) was in-
cluded in the RNA purification protocol. The RNA con-
centration of the samples was determined spectropho-
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tometrically at 260 nm. After a 1-min denaturation at
95°C, 2 g of RNA was reversed transcribed by 4 U of
Rous-associated virus (RAV-2) reverse transcriptase (Am-
ersham-Pharmacia Biotech, Uppsala, Sweden) in a 50-l
mixture consisting of reaction buffer (supplied with the
enzyme) with 250 M concentrations of dATP, dGTP,
dCTP, and dTTP (Invitrogen), 6 g of random hexanucle-
otide primers (Invitrogen), and 130 U of human placental
ribonuclease inhibitor (Amersham-Pharmacia Biotech).
The reaction was allowed to proceed for 90 min at 45°C,
whereafter the cDNA samples were stored frozen. Then,
2 l of each DNA sample was subjected to 38 cycles of
CD4-specific and 30 cycles of -actin-specific PCR on a
Biometra T3 Thermocycler (Biometra). For CD4, each
cycle comprised a 45-s denaturation step at 95°C, a 45-s
annealing step at 67°C, and a 45-s extension step at
72°C. For -actin, each cycle comprised a 45-s denatur-
ation step at 95°C, a 45-s annealing step at 63°C, and a
45-s extension step at 72°C. Oligonucleotide primer
pairs for CD4 consisted of the following nucleotide se-
quences: 5 primer (5–3) GTGAACCTGGTGGTGAT-
GAGAGC and 3 primer (5–3) GGGCTACATGTCTTCT-
GAAACCGGTG. -Actin oligonucleotide primer pairs
consisted of the 5 primer (5–3) ATCCTCACCCTGAAG-
TACCCCA and the 3 primer (5–3) GAAGGTCTCAAA-
CATGATCTGGGT. The reaction mixtures contained PCR
buffer (supplied with the enzyme), 100 M concentra-
tions of dATP, dGTP, dCTP, and dTTP (Life Technologies),
0.5 M concentrations of the forward and reverse prim-
ers, and 0.5 U of SuperTaq DNA polymerase (HT Bio-
technology) in a total volume of 25 l. After gel electro-
phoresis through a 2% agarose gel, the amplified DNA
fragments were visualized by ethidium bromide. In pre-
liminary experiments, the exponential range of the PCR
amplification curve was determined for both the CD4 and
the -actin PCRs by varying the amount of input DNA and
the number of PCR cycles. Based on these experiments,
appropriate conditions were chosen to perform the
PCRs.
Western blotting analysis
Cells were lysed in 100 l of PBS–0.5% Triton X-100
and sonnicated two times for 15 s at 0°C. Cell lysates
were next centrifuged 15 min at 4°C (15,000 g), and the
protein concentration in the supernatants was measured
using the Bio-Rad Protein Assay (Bio-Rad Laboratories
GmbH, Mu¨nchen, Germany), with BSA as a standard.
Aliquots of nonreduced protein were subjected to elec-
trophoresis on 12.5% polyacrylamide gels containing
SDS. The proteins were electroblotted onto PVDF mem-
branes (PVDF-Plus, MSI Corp.) and blocked overnight in
TBST  5% nonfat dry milk. Blots were probed with 0.66
g/ml of purified mouse antihuman CD4 mAb (BD Bio-
sciences) for 1 h at RT. After incubation with a horserad-
ish peroxidase-conjugated antimouse mAb (Jackson, PA,
U.S.A.) blots were developed using chemiluminescent
detection (ECL, Amersham).
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